#United States #Belgrade #Xtant Medical #Orthopedic Innovation #OsteoFactor Pro

Xtant Medical Launches OsteoFactor Pro™

Xtant Medical Holdings, Inc. (NYSE American: XTNT), renowned for its innovations in medical technology, has officially introduced OsteoFactor Pro™, an advanced allogeneic growth factor solution designed to accelerate bone repair. This product signifies a monumental step forward in surgical solutions aimed at treating spinal, orthopedic, and wound care issues.

A New Era for Bone Regeneration

OsteoFactor Pro™ is an intricately crafted formulation that incorporates a natural blend of growth factors crucial for enhancing bone healing. The product distinguishes itself with a unique biphasic release mechanism, which offers an immediate surge of growth factors followed by a prolonged release. This innovative approach aims to activate key biological pathways that are integral to bone regeneration, including angiogenesis (formation of new blood vessels), chemotaxis (attraction of cells), and osteogenesis (bone formation).

The launch of OsteoFactor Pro™ comes as part of Xtant Medical's ongoing commitment to advancing medical science through biologics that not only promise efficiency but also provide adaptability and significant clinical impact across various surgical procedures. This product is readily available through Xtant’s extensive distribution network throughout the United States, providing surgeons with a versatile and effective tool for promoting bone healing.

Important Features of OsteoFactor Pro™

One of the standout features of OsteoFactor Pro™ is its ability to integrate seamlessly with various orthobiologic scaffolds, including synthetic, allograft, or autograft options. This flexibility empowers surgeons to employ the solution across a range of bone regeneration strategies, enhancing its utility in clinical settings. As Mark Schallenberger, COO of Xtant Medical, notes, “This represents Xtant's leadership as the first vertically integrated company in the field, offering solutions in all five major orthobiologic categories.”

The implications of OsteoFactor Pro™ are far-reaching. It not only enhances surgeons' capabilities but also aims to significantly improve the recovery experience for patients undergoing complex procedures involving spinal fusion, deformity corrections, or degenerative conditions.

Innovations Leading the Way

The introduction of OsteoFactor Pro™ reflects Xtant Medical’s continued commitment to innovation and meeting the diverse needs of both surgeons and patients in the realm of regenerative medicine. Sean Browne, President and CEO of Xtant Medical, emphasized this dedication, stating, “Our mission is to advance the science of healing through efficient, flexible, and impactful biologics.”

Xtant Medical remains steadfast in its objective to honor the spirit of donation, ensuring that patients can live life to the fullest.

As a part of the launch process, Xtant Medical has provided detailed insights into the product's performance, which are crucial for surgeons considering its integration into their practice. The company's robust efforts in research and development underpin its standing as a leading name in medical technology.

In conclusion, the debut of OsteoFactor Pro™ not only enhances the landscape of orthopedic solutions but also solidifies Xtant Medical's position as a pivotal player in the field of medical technology, committed to continuous growth and innovative solutions that benefit healthcare practitioners and patients alike.